Medication-info.com Search Menu

Aqvesme (Mitapivat): Uses, Side Effects and Dosage

Updated:
Facts
Status:
Prescription (Rx)
Strength:
5 mg, 20 mg, 50 mg
Other brand names:
  • Aqvesme
Active ingredient:
Similar drugs:

Patient information: uses, side effects, how to take - Aqvesme

What is PYRUKYND?

PYRUKYND is a prescription medicine used to treat low red blood cell counts caused by the early breakdown of red blood cells (hemolytic anemia) in adults with pyruvate kinase deficiency (PK Deficiency).

It is not known if PYRUKYND is safe and effective in children.

Before taking PYRUKYND, tell your healthcare provider about all your medical conditions, including if you:

  • have liver problems.
  • are pregnant or plan to become pregnant. It is not known if PYRUKYND will harm your unborn baby. Tell your healthcare provider right away if you become pregnant or think that you are pregnant during treatment with PYRUKYND.

  • are breastfeeding or plan to breastfeed. It is not known if PYRUKYND passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby during treatment with PYRUKYND.

Tell your healthcare provider about all the medicines that you take, including prescription and over-the- counter medicines, vitamins, and herbal supplements.

PYRUKYND and certain other medicines may affect each other causing side effects. PYRUKYND may affect the way other medicines work, and other medicines may affect how PYRUKYND works.

Know the medicines you take. Keep a list of them to show your healthcare provider or pharmacist when you get a new medicine.

How should I take PYRUKYND?

  • Take PYRUKYND exactly as your healthcare provider tells you to take it.
  • Take PYRUKYND with or without food.

  • Swallow PYRUKYND tablets whole. Do not split, chew, crush, or dissolve the tablets.
  • Do not change your dose or stop taking PYRUKYND without talking to your healthcare provider. Your healthcare provider will give you instructions for stopping PYRUKYND. See “What are the possible side effects of PYRUKYND?”
  • If you miss a dose of PYRUKYND by 4 hours or less, take your dose as soon as possible. If more than 4 hours have passed since your regularly scheduled dose, wait for the next dose. Return to your normal schedule at the next dose.

What are the possible side effects of PYRUKYND?

PYRUKYND may cause serious side effects, including:

  • Rapid breakdown of red blood cells (acute hemolysis)has happened after suddenly interrupting or stopping treatment with PYRUKYND. You should not suddenly stop taking PYRUKYND.If you have to stop your treatment with PYRUKYND, your healthcare provider should monitor you closely. Tell your healthcare provider right away if you develop any signs or symptoms of breakdown of red blood cells including:
  • yellowing of your skin or the whites of your eyes (jaundice)
  • dark colored urine
  • dizziness
  • feeling tired
  • shortness of breath
  • confusion
  • Liver injuryhas happened in people with another condition during the first 6 months of treatment with mitapivat when given at a dose higher than recommended for people with PK deficiency. Your healthcare provider will do blood tests to check your liver before you start treatment with PYRUKYND, monthly for the first 6 months of treatment, and as needed. Your healthcare provider may temporarily or permanently stop your treatment with PYRUKYND if you have abnormal liver tests. Tell your healthcare provider right away if you develop any signs or symptoms of liver problems including:
  • yellowing of your skin or the whites of your eyes (jaundice)
  • dark colored urine
  • pain in the upper right side of your stomach area
  • nausea
  • vomiting
  • loss of appetite

The most common side effects of PYRUKYND include:

  • decrease in reproductive hormone (estrone) in men
  • increased salt from uric acid (urate) blood test
  • back pain
  • decrease in reproductive hormone (estradiol) in men
  • joint pain (arthralgia)

These are not all of the possible side effects of PYRUKYND.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store PYRUKYND?

  • Store PYRUKYND at room temperature between 68°F to 77°F (20°C to 25°C).
  • Store the blister wallets in the original carton until use.

Keep PYRUKYND and all medicines out of the reach of children.

General information about the safe and effective use of PYRUKYND.

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use PYRUKYND for a condition for which it was not prescribed. Do not give PYRUKYND to other people, even if they have the same symptoms that you have. It may harm them. You can ask your healthcare provider or pharmacist for information about PYRUKYND that is written for healthcare professionals.

What are the ingredients in PYRUKYND?

Active ingredient:mitapivat

Inactive ingredients:croscarmellose sodium, mannitol, microcrystalline cellulose, and sodium stearyl fumarate.

The tablet film coating contains: FD&C Blue No. 2, hypromellose, lactose monohydrate, titanium dioxide, and triacetin.

The tablets printed with black ink contains: ammonium hydroxide, ferrosoferric oxide, isopropyl alcohol, n-butyl alcohol, propylene glycol, and shellac glaze.

Manufactured for and Distributed by:

Agios Pharmaceuticals, Inc.

Cambridge, MA 02139

PYRUKYND® is a trademark of Agios Pharmaceuticals, Inc.

© 2022 Agios Pharmaceuticals, Inc. All rights reserved.

For more information, visit www.pyrukynd.com or call 1-833-228-8474

This Patient Information has been approved by the U.S. Food and Drug Administration. Revised: 12/2025

About this document

Source: FDA drug labeling via NLM DailyMed · Application number: NDA 216196 · View the label on DailyMed

Revision date stated in the text: December 2025

Found a mistake? Write to us via the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Drug information for Aqvesme

Rx or OTC
Prescription (Rx)?
  • This drug is available only with a prescription from a licensed healthcare provider.
  • Rx
Drug class Pyruvate Kinase Activator
Active ingredient Mitapivat
Dosage form Tablet, film coated, Kit
Route Oral
Marketing status listed in the FDA NDC Directory
Company (applicant) AGIOS PHARMS INC
FDA approval NDA 216196New Drug Application (NDA) Approved February 17, 2022
Reference listed drug This is the reference listed drug (RLD) that generics are compared with.
Manufacturers 1 labelers list this drug on DailyMed
Packages (NDC)
Package
5 mg – 14 in 1 blister pack / 4 in 1 carton NDC 71334-205-14
5 mg – 7 in 1 blister pack / 1 in 1 carton NDC 71334-220-11
20 mg – 14 in 1 blister pack / 4 in 1 carton NDC 71334-210-14
50 mg – 14 in 1 blister pack / 4 in 1 carton NDC 71334-215-14
20 mg, 5 mg – 1 in 1 carton NDC 71334-225-12
50 mg, 20 mg – 1 in 1 carton NDC 71334-230-13

Source: FDA drug labeling via NLM DailyMed, data as of October 31, 2026. FDA data (DailyMed, Orange Book, Drug Shortages, enforcement reports). Not a substitute for the advice of a doctor or pharmacist.